Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy

Wooram Um, Jooho Park, Hokyung Ko, Seungho Lim, Hong Yeol Yoon, Man Kyu Shim, Sangmin Lee, Young Ji Ko, Min Ju Kim, Jae Hyung Park, Dong Kwon Lim, Youngro Byun, Ick Chan Kwon, Kwang Meyung Kim

Research output: Contribution to journalArticle

Abstract

The therapeutic efficacy of photodynamic therapy (PDT) in cancer treatment is attributed to the conversion of tumor oxygen into reactive singlet oxygen (1O2) using photosensitizers. However, poor tissue penetration and rapid oxygen depletion have limited the effectiveness of PDT. Therefore, we have developed visible light-induced apoptosis activatable nanoparticles of the photosensitizer (Ce6)-caspase 3 cleavable peptide (Asp-Glu-Val-Asp, DEVD)-anticancer drug monomethyl auristatin E (MMAE) conjugate, resulting in Ce6-DEVD-MMAE nanoparticles. The average size of self-assembled Ce6-DEVD-MMAE nanoparticles was 90.8 ± 18.9 nm. Compared with conventional PDT based on high-energy irradiation, the new therapy uses lower-energy irradiation to induce apoptosis of cancer cells, and activation of caspase 3 to successfully cleave the anticancer drug MMAE from the Ce6-DEVD-MMAE nanoparticles, resulting in strong cytotoxic effects in cancer cells. Notably, the one-time activation of MMAE in the Ce6-DEVD-MMAE nanoparticles further amplified the cytotoxic effect resulting in additional cell death in the absence of visible light irradiation. Furthermore, Ce6-DEVD-MMAE nanoparticles passively accumulated in the targeted tumor tissues via enhanced permeation and retention (EPR) effect in mice with squamous cell carcinoma (SCC7). The high levels of toxicity were retained after exposure to lower-energy irradiation. However, Ce6-DEVD-MMAE nanoparticles did not show any toxicity in the absence of exposure to visible light irradiation, in contrast to the toxicity of free MMAE (1–10 nM). Thus, the light-induced therapeutic strategy based on apoptotic activation of Ce6-DEVD-MMAE nanoparticles can be used to treat solid tumors inaccessible to conventional PDT.

Original languageEnglish
Article number119494
JournalBiomaterials
Volume224
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Photosensitizing Agents
Photosensitizers
Cell death
Nanoparticles
Apoptosis
Light
Photodynamic therapy
Pharmaceutical Preparations
Irradiation
Neoplasms
Photochemotherapy
Toxicity
Tumors
Chemical activation
Therapeutics
Oxygen
Cells
Tissue
Caspase 3
Oncology

Keywords

  • Apoptosis
  • Cytotoxic prodrug
  • Nanomedicine
  • Photodynamic therapy
  • Self-assembly
  • Targeted cancer therapy

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy. / Um, Wooram; Park, Jooho; Ko, Hokyung; Lim, Seungho; Yoon, Hong Yeol; Shim, Man Kyu; Lee, Sangmin; Ko, Young Ji; Kim, Min Ju; Park, Jae Hyung; Lim, Dong Kwon; Byun, Youngro; Kwon, Ick Chan; Kim, Kwang Meyung.

In: Biomaterials, Vol. 224, 119494, 01.12.2019.

Research output: Contribution to journalArticle

Um, W, Park, J, Ko, H, Lim, S, Yoon, HY, Shim, MK, Lee, S, Ko, YJ, Kim, MJ, Park, JH, Lim, DK, Byun, Y, Kwon, IC & Kim, KM 2019, 'Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy', Biomaterials, vol. 224, 119494. https://doi.org/10.1016/j.biomaterials.2019.119494
Um, Wooram ; Park, Jooho ; Ko, Hokyung ; Lim, Seungho ; Yoon, Hong Yeol ; Shim, Man Kyu ; Lee, Sangmin ; Ko, Young Ji ; Kim, Min Ju ; Park, Jae Hyung ; Lim, Dong Kwon ; Byun, Youngro ; Kwon, Ick Chan ; Kim, Kwang Meyung. / Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy. In: Biomaterials. 2019 ; Vol. 224.
@article{8ef4f3522a4541c9addce490f86ec531,
title = "Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy",
abstract = "The therapeutic efficacy of photodynamic therapy (PDT) in cancer treatment is attributed to the conversion of tumor oxygen into reactive singlet oxygen (1O2) using photosensitizers. However, poor tissue penetration and rapid oxygen depletion have limited the effectiveness of PDT. Therefore, we have developed visible light-induced apoptosis activatable nanoparticles of the photosensitizer (Ce6)-caspase 3 cleavable peptide (Asp-Glu-Val-Asp, DEVD)-anticancer drug monomethyl auristatin E (MMAE) conjugate, resulting in Ce6-DEVD-MMAE nanoparticles. The average size of self-assembled Ce6-DEVD-MMAE nanoparticles was 90.8 ± 18.9 nm. Compared with conventional PDT based on high-energy irradiation, the new therapy uses lower-energy irradiation to induce apoptosis of cancer cells, and activation of caspase 3 to successfully cleave the anticancer drug MMAE from the Ce6-DEVD-MMAE nanoparticles, resulting in strong cytotoxic effects in cancer cells. Notably, the one-time activation of MMAE in the Ce6-DEVD-MMAE nanoparticles further amplified the cytotoxic effect resulting in additional cell death in the absence of visible light irradiation. Furthermore, Ce6-DEVD-MMAE nanoparticles passively accumulated in the targeted tumor tissues via enhanced permeation and retention (EPR) effect in mice with squamous cell carcinoma (SCC7). The high levels of toxicity were retained after exposure to lower-energy irradiation. However, Ce6-DEVD-MMAE nanoparticles did not show any toxicity in the absence of exposure to visible light irradiation, in contrast to the toxicity of free MMAE (1–10 nM). Thus, the light-induced therapeutic strategy based on apoptotic activation of Ce6-DEVD-MMAE nanoparticles can be used to treat solid tumors inaccessible to conventional PDT.",
keywords = "Apoptosis, Cytotoxic prodrug, Nanomedicine, Photodynamic therapy, Self-assembly, Targeted cancer therapy",
author = "Wooram Um and Jooho Park and Hokyung Ko and Seungho Lim and Yoon, {Hong Yeol} and Shim, {Man Kyu} and Sangmin Lee and Ko, {Young Ji} and Kim, {Min Ju} and Park, {Jae Hyung} and Lim, {Dong Kwon} and Youngro Byun and Kwon, {Ick Chan} and Kim, {Kwang Meyung}",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.biomaterials.2019.119494",
language = "English",
volume = "224",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy

AU - Um, Wooram

AU - Park, Jooho

AU - Ko, Hokyung

AU - Lim, Seungho

AU - Yoon, Hong Yeol

AU - Shim, Man Kyu

AU - Lee, Sangmin

AU - Ko, Young Ji

AU - Kim, Min Ju

AU - Park, Jae Hyung

AU - Lim, Dong Kwon

AU - Byun, Youngro

AU - Kwon, Ick Chan

AU - Kim, Kwang Meyung

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The therapeutic efficacy of photodynamic therapy (PDT) in cancer treatment is attributed to the conversion of tumor oxygen into reactive singlet oxygen (1O2) using photosensitizers. However, poor tissue penetration and rapid oxygen depletion have limited the effectiveness of PDT. Therefore, we have developed visible light-induced apoptosis activatable nanoparticles of the photosensitizer (Ce6)-caspase 3 cleavable peptide (Asp-Glu-Val-Asp, DEVD)-anticancer drug monomethyl auristatin E (MMAE) conjugate, resulting in Ce6-DEVD-MMAE nanoparticles. The average size of self-assembled Ce6-DEVD-MMAE nanoparticles was 90.8 ± 18.9 nm. Compared with conventional PDT based on high-energy irradiation, the new therapy uses lower-energy irradiation to induce apoptosis of cancer cells, and activation of caspase 3 to successfully cleave the anticancer drug MMAE from the Ce6-DEVD-MMAE nanoparticles, resulting in strong cytotoxic effects in cancer cells. Notably, the one-time activation of MMAE in the Ce6-DEVD-MMAE nanoparticles further amplified the cytotoxic effect resulting in additional cell death in the absence of visible light irradiation. Furthermore, Ce6-DEVD-MMAE nanoparticles passively accumulated in the targeted tumor tissues via enhanced permeation and retention (EPR) effect in mice with squamous cell carcinoma (SCC7). The high levels of toxicity were retained after exposure to lower-energy irradiation. However, Ce6-DEVD-MMAE nanoparticles did not show any toxicity in the absence of exposure to visible light irradiation, in contrast to the toxicity of free MMAE (1–10 nM). Thus, the light-induced therapeutic strategy based on apoptotic activation of Ce6-DEVD-MMAE nanoparticles can be used to treat solid tumors inaccessible to conventional PDT.

AB - The therapeutic efficacy of photodynamic therapy (PDT) in cancer treatment is attributed to the conversion of tumor oxygen into reactive singlet oxygen (1O2) using photosensitizers. However, poor tissue penetration and rapid oxygen depletion have limited the effectiveness of PDT. Therefore, we have developed visible light-induced apoptosis activatable nanoparticles of the photosensitizer (Ce6)-caspase 3 cleavable peptide (Asp-Glu-Val-Asp, DEVD)-anticancer drug monomethyl auristatin E (MMAE) conjugate, resulting in Ce6-DEVD-MMAE nanoparticles. The average size of self-assembled Ce6-DEVD-MMAE nanoparticles was 90.8 ± 18.9 nm. Compared with conventional PDT based on high-energy irradiation, the new therapy uses lower-energy irradiation to induce apoptosis of cancer cells, and activation of caspase 3 to successfully cleave the anticancer drug MMAE from the Ce6-DEVD-MMAE nanoparticles, resulting in strong cytotoxic effects in cancer cells. Notably, the one-time activation of MMAE in the Ce6-DEVD-MMAE nanoparticles further amplified the cytotoxic effect resulting in additional cell death in the absence of visible light irradiation. Furthermore, Ce6-DEVD-MMAE nanoparticles passively accumulated in the targeted tumor tissues via enhanced permeation and retention (EPR) effect in mice with squamous cell carcinoma (SCC7). The high levels of toxicity were retained after exposure to lower-energy irradiation. However, Ce6-DEVD-MMAE nanoparticles did not show any toxicity in the absence of exposure to visible light irradiation, in contrast to the toxicity of free MMAE (1–10 nM). Thus, the light-induced therapeutic strategy based on apoptotic activation of Ce6-DEVD-MMAE nanoparticles can be used to treat solid tumors inaccessible to conventional PDT.

KW - Apoptosis

KW - Cytotoxic prodrug

KW - Nanomedicine

KW - Photodynamic therapy

KW - Self-assembly

KW - Targeted cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=85072302609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072302609&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2019.119494

DO - 10.1016/j.biomaterials.2019.119494

M3 - Article

C2 - 31542518

AN - SCOPUS:85072302609

VL - 224

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

M1 - 119494

ER -